Terms: = Gastric cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Clinical Outcome
11 results:
1. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
[TBL] [Abstract] [Full Text] [Related]
2. Sym015: A Highly Efficacious Antibody Mixture against
Poulsen TT; Grandal MM; Skartved NJØ; Hald R; Alifrangis L; Koefoed K; Lindsted T; Fröhlich C; Pollmann SE; Eriksen KW; Dahlman A; Jacobsen HJ; Bouquin T; Pedersen MW; Horak ID; Lantto J; Kragh M
Clin Cancer Res; 2017 Oct; 23(19):5923-5935. PubMed ID: 28679766
[No Abstract] [Full Text] [Related]
3. Anti-c-met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with met amplification.
Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
[TBL] [Abstract] [Full Text] [Related]
4. Extent of lymph node dissection for adenocarcinoma of the stomach.
Mocellin S; McCulloch P; Kazi H; Gama-Rodrigues JJ; Yuan Y; Nitti D
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD001964. PubMed ID: 26267122
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic impact of the c-met polymorphism on the clinical outcome in locoregional gastric cancer patients.
Sunakawa Y; Wakatsuki T; Yang D; Zhang W; Ning Y; Stintzing S; Stremitzer S; Yamauchi S; Sebio A; El-khoueiry R; Iqbal S; Barzi A; Gerger A; Stotz M; Azuma M; Watanabe M; Koizumi W; Lenz HJ
Pharmacogenet Genomics; 2014 Dec; 24(12):588-96. PubMed ID: 25203738
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic significance of met amplification and expression in gastric cancer: a systematic review with meta-analysis.
Peng Z; Zhu Y; Wang Q; Gao J; Li Y; Li Y; Ge S; Shen L
PLoS One; 2014; 9(1):e84502. PubMed ID: 24416238
[TBL] [Abstract] [Full Text] [Related]
7. Advanced gastric cancer: is there enough evidence to call second-line therapy standard?
Arkenau HT; Saggese M; Lemech C
World J Gastroenterol; 2012 Nov; 18(44):6376-8. PubMed ID: 23197882
[TBL] [Abstract] [Full Text] [Related]
8. met in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.
Lee HE; Kim MA; Lee HS; Jung EJ; Yang HK; Lee BL; Bang YJ; Kim WH
Br J Cancer; 2012 Jul; 107(2):325-33. PubMed ID: 22644302
[TBL] [Abstract] [Full Text] [Related]
9. Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.
Hsu C; Shen YC; Cheng CC; Cheng AL; Hu FC; Yeh KH
Gastric Cancer; 2012 Jul; 15(3):265-80. PubMed ID: 22576708
[TBL] [Abstract] [Full Text] [Related]
10. met activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract] [Full Text] [Related]
11. gastric cancer in the era of molecularly targeted agents: current drug development strategies.
Arkenau HT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):855-66. PubMed ID: 19363621
[TBL] [Abstract] [Full Text] [Related]
